Viatris Inc. and Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced May 19th, that Abevmy® (bevacizumab) is now available in Canada. Abevmy, co-developed...
Pfizer's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush...
NexImmune, Inc., Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb...
Cerebras Systems, the pioneer in high performance artificial intelligence (AI) computing, and AbbVie, a global biopharmaceutical company, announced a landmark achievement in AbbVie’s AI...
EuroAPI, Sanofi’s pharmaceutical-ingredients spinoff, rose on its first trading day in Paris, in an early sign that appetite is recovering in Europe’s dormant listings...